News stories about ProQR Therapeutics N.V. (NASDAQ:PRQR) have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ProQR Therapeutics N.V. earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.5046348122787 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Several analysts have issued reports on the stock. ValuEngine downgraded shares of ProQR Therapeutics N.V. from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of ProQR Therapeutics N.V. in a research note on Tuesday, September 26th. Leerink Swann reissued an “outperform” rating and issued a $12.00 price objective (up previously from $10.00) on shares of ProQR Therapeutics N.V. in a research note on Tuesday, September 26th. JMP Securities raised their price objective on shares of ProQR Therapeutics N.V. from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 26th. Finally, Zacks Investment Research raised shares of ProQR Therapeutics N.V. from a “hold” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $16.40.
Shares of ProQR Therapeutics N.V. (NASDAQ PRQR) traded down 1.30% during trading on Tuesday, hitting $3.80. 37,439 shares of the stock were exchanged. ProQR Therapeutics N.V. has a one year low of $3.65 and a one year high of $6.90. The stock’s 50 day moving average price is $4.82 and its 200-day moving average price is $4.98. The company’s market cap is $91.60 million.
WARNING: “ProQR Therapeutics N.V. (PRQR) Given News Impact Rating of 0.09” was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/10/31/proqr-therapeutics-n-v-prqr-given-news-impact-rating-of-0-09.html.
ProQR Therapeutics N.V. Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.
What are top analysts saying about ProQR Therapeutics N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ProQR Therapeutics N.V. and related companies.